Prosecution Insights
Last updated: November 04, 2026

Cellatoz Therapeutics Inc.

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Cellatoz Therapeutics Inc. has 1 pending office action. This action is assigned to 1 distinct examiner and 1 distinct art unit. Lora E Barnhart Driscoll is the busiest examiner for the portfolio, managing the 1 pending office action. The current prosecution activity is focused on this single examiner and art unit. The outcome of the company's patent application is dependent on the review of this individual within the specified art unit.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
0
Medium (0%)
1
Easy (100%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

0
Life Sciences
0% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
100% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
DRISCOLL, LORA E BARNHART 1 32.1% +20.8%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
19061752 MUSCULOSKELETAL STEM CELL AND MEDIUM FOR INDUCING DIFFERENTIATION OF MUSCULOSKELETAL STEM CELL DRISCOLL, LORA E BARNHART —

Top Art Units

Art UnitApps
3991 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19061752 MUSCULOSKELETAL STEM CELL AND MEDIUM FOR INDUCING DIFFERENTIATION OF MUSCULOSKELETAL STEM CELL DRISCOLL, LORA E BARNHART 3991 §112 Non-Final OA — Pending Feb 24, 2025

Managing Cellatoz Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Cellatoz Therapeutics Inc. have?

Cellatoz Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Cellatoz Therapeutics Inc. applications?

Lora E Barnhart Driscoll has the most, with 1 of Cellatoz Therapeutics Inc.'s pending office actions.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month